Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Drops By 15.7%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 4,250,000 shares, a drop of 15.7% from the January 31st total of 5,040,000 shares. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 1.5 days.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds have recently modified their holdings of RVPH. Raymond James Financial Inc. acquired a new position in Reviva Pharmaceuticals in the fourth quarter valued at about $25,000. Cornerstone Select Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 4th quarter valued at approximately $32,000. Drive Wealth Management LLC acquired a new position in shares of Reviva Pharmaceuticals in the 4th quarter worth approximately $36,000. XTX Topco Ltd purchased a new position in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $45,000. Finally, Tower Research Capital LLC TRC increased its holdings in Reviva Pharmaceuticals by 848.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after purchasing an additional 23,953 shares during the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Trading Up 0.4 %

Reviva Pharmaceuticals stock traded up $0.01 during mid-day trading on Wednesday, hitting $1.26. The company’s stock had a trading volume of 351,072 shares, compared to its average volume of 1,836,978. The stock’s fifty day moving average is $1.79 and its two-hundred day moving average is $1.47. The firm has a market capitalization of $41.97 million, a PE ratio of -1.13 and a beta of -0.12. Reviva Pharmaceuticals has a 1 year low of $0.60 and a 1 year high of $4.28.

Analyst Upgrades and Downgrades

RVPH has been the subject of several research reports. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 price objective for the company. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. HC Wainwright reduced their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. Finally, Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.